|
- Johnson Johnson Reports Q2 2025 Results; Raises 2025 Outlook
NEW BRUNSWICK, N J -- (BUSINESS WIRE)-- Johnson Johnson (NYSE: JNJ) today announced results for second-quarter 2025 “Today’s strong results reflect the depth and strength of Johnson Johnson’s uniquely diversified business operating across both MedTech and Innovative Medicine,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson Johnson “Our portfolio and
- Contact us - Johnson Johnson
Get in touch with Johnson JohnsonDo not sell or share my personal information Limit the use of my sensitive personal information
- Johnson Johnson Reports Q4 and Full-Year 2024 Results
NEW BRUNSWICK, N J -- (BUSINESS WIRE)-- Johnson Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2024 "2024 was a transformative year for Johnson Johnson, marked by strong growth, an accelerating pipeline and industry-leading investments in innovation,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson Johnson “As a healthcare company
- Global Johnson Johnson websites
If you don’t see your country or region represented above, please click below to find links to the company’s Innovative Medicine and MedTech country and regional websites
- Explore Johnson Johnson careers in Mexico | Johnson Johnson Careers
Discover exciting career opportunities at Johnson Johnson in Mexico Search job openings and apply now to join a global leader in healthcare innovation
- Products - Johnson Johnson
Learn about Johnson Johnson's extensive portfolio of healthcare products Find solutions to meet your medical and wellness needs
- Explore careers at Johnson Johnson | Johnson Johnson Careers
Elevate your career with J J Discover global job opportunities to drive innovation, impact lives and grow in a supportive, mission-driven culture
- Pipeline - Innovative Medicine pipeline | Johnson Johnson - Investors
Development pipeline Select programs in development, Phase 1 through Approval (removed after programs achieve approval in both US EU) Learn more
|
|
|